Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  18,303 results for ""Angiotensin II Type 1 Receptor Blockers""

Your Filters

Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

A Bioequivalence Study of Azilsartan in Healthy Chinese Subjects.

  • Authors : Liu X; Anqing Medical College, Anqing, China.; Dai X

Subjects: Angiotensin II Type 1 Receptor Blockers*/Angiotensin II Type 1 Receptor Blockers*/Angiotensin II Type 1 Receptor Blockers*/pharmacokinetics ; Angiotensin II Type 1 Receptor Blockers*/Angiotensin II Type 1 Receptor Blockers*/Angiotensin II Type 1 Receptor Blockers*/administration & dosage ; Angiotensin II Type 1 Receptor Blockers*/Angiotensin II Type 1 Receptor Blockers*/Angiotensin II Type 1 Receptor Blockers*/adverse effects

  • Source: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2024 Dec; Vol. 13 (12), pp. 1301-1307. Date of Electronic Publication: 2024 Oct 18.Publisher: Wiley Country of Publication: United States NLM ID: 101572899 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Dual blockade of endothelin A and angiotensin II type 1 receptors with sparsentan as a novel treatment strategy to alleviate IgA nephropathy.

  • Authors : Nagasawa H; Department of Nephrology, Juntendo University Faculty of Medicine, Tokyo, Japan.; Division of Kidney Health and Aging, The Center for Integrated Kidney Research and Advance, Shimane University Faculty of Medicine, Shimane, Japan.

Subjects: Glomerulonephritis, IGA*/Glomerulonephritis, IGA*/Glomerulonephritis, IGA*/drug therapy ; Glomerulonephritis, IGA*/Glomerulonephritis, IGA*/Glomerulonephritis, IGA*/physiopathology ; Glomerulonephritis, IGA*/Glomerulonephritis, IGA*/Glomerulonephritis, IGA*/pathology

  • Source: Expert opinion on investigational drugs [Expert Opin Investig Drugs] 2024 Nov; Vol. 33 (11), pp. 1143-1152. Date of Electronic Publication: 2024 Oct 18.Publisher: Taylor & Francis Country of Publication: England NLM ID: 9434197 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Olmesartan: 360-degree Perspectives Befitting an Angiotensin Receptor Blocker.

  • Authors : Shetty S; Chairman and Managing Director, Sadanand Healthy Living Centre Ltd., Mumbai, Maharashtra, India.; Bhoraskar A

Subjects: Tetrazoles*/Tetrazoles*/Tetrazoles*/therapeutic use ; Hypertension*/Hypertension*/Hypertension*/drug therapy ; Imidazoles*/Imidazoles*/Imidazoles*/therapeutic use

  • Source: The Journal of the Association of Physicians of India [J Assoc Physicians India] 2024 Dec; Vol. 72 (12), pp. 59-72.Publisher: Association of Physicians of India Country of Publication: India NLM ID: 7505585 Publication Model: Print Cited Medium: Print ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Renin-angiotensin blockade ameliorates the progression of glomerular injury in podocyte-specific Ctcf knockout mice.

  • Authors : Fujioka K; Department of Pediatrics, Institute of Health Biosciences, The Tokushima University Graduate School, Tokushima, Japan.; Nagai T

Subjects: Podocytes*/Podocytes*/Podocytes*/metabolism ; Podocytes*/Podocytes*/Podocytes*/drug effects ; Podocytes*/Podocytes*/Podocytes*/pathology

  • Source: Nephrology (Carlton, Vic.) [Nephrology (Carlton)] 2024 Dec; Vol. 29 (12), pp. 815-824. Date of Electronic Publication: 2024 Sep 30.Publisher: Blackwell Science Country of Publication: Australia NLM ID: 9615568 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

The protective effect of angiotensin II type I receptor blocker (valsartan) on behavioral impairment, NLRP3, BDNF, and oxidative stress in the brain tissue of ovariectomized female rats.

  • Authors : Erdem S; Ahmet Erdoğan Vocational School of Health Services, Pathology Program, Zonguldak Bülent Ecevit University, Zonguldak, Turkey.; Özaçmak HS

Subjects: Angiotensin II Type 1 Receptor Blockers*/Angiotensin II Type 1 Receptor Blockers*/Angiotensin II Type 1 Receptor Blockers*/pharmacology ; Anxiety*/Anxiety*/Anxiety*/drug therapy ; Anxiety*/Anxiety*/Anxiety*/metabolism

  • Source: Physiological reports [Physiol Rep] 2024 Oct; Vol. 12 (20), pp. e70003.Publisher: published by Wiley Periodicals, Inc. on behalf of the American Physiological Society and The Physiological Society Country of Publication: United States NLM

Record details

Read More Add to Saved list
×
Academic Journal

The Combination of Valsartan and Spironolactone Mitigated Mitral Regurgitation-Induced Cardiac Dysfunction in a Novel Rat Model.

  • Authors : Chang WT; School of Medicine and Doctoral Program of Clinical and Experimental Medicine, College of Medicine and Center of Excellence for Metabolic Associated Fatty Liver Disease, National Sun Yat-sen University, Kaohsiung, Taiwan.; Division of Cardiology, Department of Internal Medicine, Chi Mei Medical Center, Tainan

Subjects: Valsartan* ; Spironolactone*/Spironolactone*/Spironolactone*/pharmacology ; Mineralocorticoid Receptor Antagonists*/Mineralocorticoid Receptor Antagonists*/Mineralocorticoid Receptor Antagonists*/pharmacology

  • Source: Journal of cardiovascular pharmacology [J Cardiovasc Pharmacol] 2024 Oct 01; Vol. 84 (4), pp. 410-417. Date of Electronic Publication: 2024 Oct 01.Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 7902492 Publication Model: Electronic Cited Medium: Internet

Record details

Read More Add to Saved list
×
Academic Journal

Anti-tumor effects of telmisartan in glioma-astrocyte non-contact co-cultures: A critical role of astrocytic IL-6-mediated paracrine growth promotion.

  • Authors : Quan W; Department of Neurosurgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.; Xu CS

Subjects: Telmisartan*/Telmisartan*/Telmisartan*/pharmacology ; Telmisartan*/Telmisartan*/Telmisartan*/therapeutic use ; Astrocytes*/Astrocytes*/Astrocytes*/drug effects

  • Source: International immunopharmacology [Int Immunopharmacol] 2024 Sep 30; Vol. 139, pp. 112707. Date of Electronic Publication: 2024 Jul 19.Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 100965259 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Safety and efficacy of sparsentan versus irbesartan in focal segmental glomerulosclerosis and IgA nephropathy: a systematic review and meta-analysis of randomized controlled trials.

Subjects: Angiotensin II Type 1 Receptor Blockers*/Angiotensin II Type 1 Receptor Blockers*/Angiotensin II Type 1 Receptor Blockers*/administration & dosage ; Angiotensin II Type 1 Receptor Blockers*/Angiotensin II Type 1 Receptor Blockers*/Angiotensin II Type 1 Receptor Blockers*/adverse effects ; Glomerulonephritis, IGA*/Glomerulonephritis, IGA*/Glomerulonephritis, IGA*/complications

  • Source: BMC nephrology [BMC Nephrol] 2024 Sep 27; Vol. 25 (1), pp. 316. Date of Electronic Publication: 2024 Sep 27.Publisher: BioMed Central Country of Publication: England NLM ID: 100967793 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2369

Record details

Read More Add to Saved list
×
Academic Journal

Effects of Telmisartan on Intraocular Pressure, Blood Pressure, and Ocular Perfusion Pressure in Normal and Glaucomatous Cats.

  • Authors : Oikawa K; Surgical Sciences, University of Wisconsin-Madison, Madison, WI, USA.; Ophthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, WI, USA.

Subjects: Telmisartan*/Telmisartan*/Telmisartan*/pharmacology ; Telmisartan*/Telmisartan*/Telmisartan*/therapeutic use ; Telmisartan*/Telmisartan*/Telmisartan*/administration & dosage

  • Source: Translational vision science & technology [Transl Vis Sci Technol] 2024 Sep 03; Vol. 13 (9), pp. 15.Publisher: Association for Research in Vision and Ophthalmology Country of Publication: United States NLM ID: 101595919 Publication Model: Print Cited

Record details

Read More Add to Saved list
×
Academic Journal

Reduction of Aversive Learning Rates in Pavlovian Conditioning by Angiotensin II Antagonist Losartan: A Randomized Controlled Trial.

  • Authors : Zika O; Max Planck Institute for Human Development, Berlin, Germany.; Appel J

Subjects: Losartan*/Losartan*/Losartan*/pharmacology ; Losartan*/Losartan*/Losartan*/administration & dosage ; Conditioning, Classical*/Conditioning, Classical*/Conditioning, Classical*/drug effects

  • Source: Biological psychiatry [Biol Psychiatry] 2024 Aug 15; Vol. 96 (4), pp. 247-255. Date of Electronic Publication: 2024 Feb 02.Publisher: Elsevier Country of Publication: United States NLM ID: 0213264 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
  • 1-10 of  18,303 results for ""Angiotensin II Type 1 Receptor Blockers""